CPT® Code 87801

Quick Reference: CPT 87801

• Definition: CPT 87801 represents infectious agent detection by nucleic acid (DNA/RNA), multiple organisms using an amplified probe technique (typically NAAT/PCR) performed as one multiplex procedure on a specimen.
• What it means operationally: It is a single-kit / single-run code for a test that simultaneously evaluates multiple pathogen targets. When one method or one kit detects multiple organisms, CMS bundling policy generally expects one unit of a multi-organism code, not multiple single-organism codes.
• CLIA requirements: 87801 is usually moderate/high complexity. Most labs billing 87801 must hold an appropriate CLIA certificate. A narrow exception exists for specific FDA-authorized CLIA-waived multiplex NAATs, where 87801QW may apply.
• Not for COVID-only tests: A single-pathogen SARS-CoV-2 NAAT is billed with the dedicated code 87635, not 87801.
• Documentation expectations: The lab record should name the panel/test, indicate NAAT/PCR methodology, and identify the pathogens included so the claim clearly reflects a multiplex panel rather than unbundled component testing.
• Coverage reality: Even when 87801 is technically correct, payers may apply coverage limits for syndromic panels. Medicare LCDs for molecular syndromic panels can restrict scope and medical necessity, especially in outpatient testing.

CPT 87801 sits at the intersection of modern molecular diagnostics and payer utilization controls. Clinically, multiplex NAAT panels can shorten time-to-diagnosis, reduce unnecessary antibiotics, and support infection control decisions. Administratively, those same panels are high-cost, high-impact services that payers scrutinize for overuse, duplicate billing, and improper unbundling. In 2026, accurate 87801 billing requires aligning the claim with three facts that auditors care about: (1) what the platform actually did (one multiplex procedure vs multiple singleplex assays), (2) whether a more specific CPT code exists for that exact test situation, and (3) whether medical necessity documentation supports the panel’s size and context.

This guide explains the code descriptor and methodology, the practical boundaries for “multiple organisms,” CLIA certification (including rare 87801QW scenarios), Medicare/NCCI bundling expectations, payer coverage considerations for syndromic panels, modifier rules, and documentation standards. The focus is compliance: how to report 87801 when appropriate, and how to avoid the most common denial drivers (panel unbundling and code selection conflicts).

flowchart TD
    A["Infectious agent NAAT ordered"] --> B{"Multiple organisms\ntested in one run?"}
    B -->|"No"| C{"SARS-CoV-2 only?"}
    C -->|"Yes"| D["Bill 87635"]
    C -->|"No"| E["Bill organism-specific\nNAAT code"]
    B -->|"Yes"| F{"Panel-specific CPT\ncode exists?"}
    F -->|"Yes"| G["Bill panel-specific code"]
    F -->|"No"| H{"Amplified probe /\nNAAT method?"}
    H -->|"No"| I["Use non-amplified\nmulti-organism code"]
    H -->|"Yes"| J{"Test is CLIA-waived?"}
    J -->|"Yes"| K["Bill 87801QW"]
    J -->|"No"| L["Bill 87801"]

CPT 87801 Description and Methodology

CPT 87801 is defined in CPT resources as a multi-organism infectious agent test performed by nucleic acid detection using an amplified probe technique. “Amplified probe” is payer and coding shorthand for NAAT methods that amplify target genetic material (DNA or RNA) to improve analytical sensitivity. In practical laboratory operations, 87801 most often corresponds to multiplex PCR or multiplex RT-PCR (for RNA viruses), and may also correspond to other amplification formats depending on platform design.

Direct probe vs amplified probe (why the distinction matters)

Historically, nucleic-acid testing was divided into non-amplified probe tests (direct hybridization) and amplified tests (PCR/NAAT). Amplification changes both sensitivity and reimbursement behavior. CMS bundling language in educational guidance emphasizes that when one method, one procedure, or one kit is used to test multiple organisms, the service is reported as one unit of the appropriate multi-organism code. That “one-kit = one code” logic is a foundational concept for multiplex billing and is often the payer’s primary objection when they see many component codes submitted for a single cartridge-based panel.

What triggers correct 87801 use

Use 87801 when all of the following are true:

• Multiple organisms are tested in one analytical procedure (one panel run, one cartridge, one kit, or one integrated platform process).
• The methodology is amplified NAAT (not a non-amplified direct probe method).
• No more specific CPT code fits the exact test format (for example, no panel-specific code that the payer expects for that target count or syndrome).

The third point is increasingly important. In recent years, CPT introduced panel-specific codes for common syndromes (respiratory panels, GI panels, and other defined groupings). When those codes apply, they generally replace reliance on older “catch-all” multiplex coding. As a result, 87801 is most defensible for smaller, less standardized multiplex assays, niche multi-organism NAATs, or unusual combinations that do not map neatly to existing panel codes.

Practical interpretation: If you can name the exact commercial panel and it is widely used, there is a high likelihood that a more specific CPT code exists in 2026. 87801 becomes more common when the assay is an LDT multiplex or a niche point-of-care multiplex with limited targets that does not match a dedicated descriptor.

Eligible Panels, Panel-Specific Codes, and Platform Context

Conceptually, 87801 covers multiplex NAAT panels used in respiratory, gastrointestinal, genitourinary, and other infectious syndromes. However, correct code selection depends less on the clinical syndrome and more on the relationship between the assay and the CPT code structure. Medicare-oriented guidance stresses that multi-organism tests performed with one kit are reported as one multi-organism service, and coverage policy then evaluates whether that panel was reasonable and necessary in the clinical setting.

Panel code precedence and why 87801 may be “technically right but operationally denied”

Even if a test is unquestionably multiplex, payers may expect a panel-specific code rather than 87801. The risk is not only denial for “wrong code,” but also denial through coverage logic that is attached to the panel category. LCDs for molecular syndromic panels can set expectations about panel size, setting (outpatient vs inpatient), and indications. Therefore, laboratories should treat 87801 as a last-resort multiplex code used when panel-specific coding does not apply, rather than as a default multiplex code for any respiratory or GI panel.

Platform documentation: why naming the platform matters even when CPT is correct

Audits commonly focus on whether the claim reflects what the lab actually ran. If the record names a multiplex platform and lists multiple targets, then a single multiplex code is coherent. If the record looks like multiple separate singleplex PCRs, then 87801 may be questioned. CMS educational materials emphasize correct billing for panels (one unit for one test kit/procedure), and platform naming supports that interpretation. The lab report should identify the test name (for example “Respiratory panel NAAT”), specimen type, and target list or menu.

For GI panels specifically, manufacturers publish insurance and coding guidance that illustrates how large multiplex panels map to defined CPT panel codes rather than generic multi-organism coding. The BioFire GI Panel insurance guide is an example resource frequently used by billing teams to understand panel coding and payer expectations. Even when a lab is not using the BioFire platform, these manufacturer documents are useful because they illustrate a general payer posture: standardized panels usually have standardized coding pathways.

CLIA Certification and Test Classification (Including 87801QW)

Most tests reported with CPT 87801 are molecular multiplex assays performed in moderate- or high-complexity laboratories. From a billing compliance standpoint, two CLIA issues matter: (1) whether the laboratory has the appropriate CLIA certification level for the performed test, and (2) whether Medicare requires the QW modifier for a specific waived assay. When these are wrong, claims can deny even if the CPT code selection is otherwise accurate.

Baseline rule: 87801 is usually not waived

As a general expectation, 87801 corresponds to advanced multiplex NAAT testing that is not CLIA-waived. That means a CLIA Certificate of Waiver is usually insufficient for performing and billing the service. Laboratories should maintain evidence of test complexity classification and ensure payer enrollment records match the lab’s CLIA certificate type.

Narrow exception: CMS recognized 87801QW for specific waived multiplex NAATs

CMS issued guidance on new waived tests that included the addition of 87801QW effective March 30, 2021 for certain waived multiplex NAATs. The practical implication is that some point-of-care multiplex NAAT kits (not all) may use 87801 with QW when they are FDA-authorized as waived and CMS recognizes the waived billing configuration.

Texas Medicaid provides an example of payer-facing operationalization: it published guidance that a QW modifier is required for procedure code 87801 when the performed test is CLIA-waived, and also emphasized that the provider must have the necessary CLIA certification on file for claims processing. Even if your organization is not billing Texas Medicaid, this illustrates the broader point: payers may reject 87801 claims when CLIA enrollment data or modifier use does not match the test’s regulatory classification.

CLIA compliance checkpoint: If a site is CLIA-waived and wants to bill 87801, it should only do so when (a) the specific assay is CLIA-waived and (b) payer rules recognize that assay under 87801QW. Otherwise, the correct action is to refer the test to a moderate/high complexity lab or to use a different waived test method that matches the site’s certification.

Medicare, NCCI Bundling, and Coverage Policy Framework

Medicare payment logic for multiplex NAAT panels is shaped by two related concepts: NCCI bundling rules (which focus on how to code a single multiplex service) and coverage policies/LCDs (which focus on when that service is medically necessary). In denial analysis, bundling denials often look like duplicate services or unbundled component billing, while coverage denials often look like “not reasonable and necessary.” 87801 claims can trigger both.

One-kit/one-procedure principle and component billing limits

CMS-aligned educational guidance for billing infectious disease panels states that when multiple organisms are tested using one procedure, one methodology, or one test kit, the test is reported with one unit of service for the multi-organism code, and component tests are not separately billable in that context. The compliance risk is high when a lab bills 87801 and also bills individual organism NAAT codes for pathogens contained in the same run, or when it bills multiple single-organism codes that effectively represent one multiplex kit. In post-payment review, such billing can be characterized as unbundling.

Coverage posture: molecular syndromic panel LCD logic

Coverage policies for molecular syndromic panels evaluate the clinical rationale for using multiplex testing rather than targeted testing. MolDX LCDs and related Medicare coverage database content describe expectations and limitations for syndromic panels. These policies can limit coverage by patient setting (for example outpatient vs inpatient), by clinical indications, and by panel size or syndrome category. The presence of a multiplex code does not guarantee coverage; it only describes what was done.

In practice, the strongest medical necessity documentation includes: symptom severity, risk factors (immunocompromise, transplant, severe COPD, pregnancy when relevant), time-sensitive decision-making (antivirals, isolation), and prior negative results when escalation to a broader panel is justified. Documentation should show that the panel result meaningfully affected clinical management, not merely that it was available.

COVID-only testing is a code selection issue, not just a coverage issue

Using 87801 for a single SARS-CoV-2 NAAT is a frequent coding error. The AMA published long descriptors for coronavirus-related coding that include the dedicated SARS-CoV-2 NAAT code 87635. When only SARS-CoV-2 is tested (even if the platform is capable of more), 87635 is the appropriate code. 87801 is reserved for true multi-organism panels where multiple targets are actually tested in the performed assay.

Modifier Use and Frequency Limitations

Most clean 87801 claims have no modifier. However, there are two modifier topics that matter in practice: the QW modifier for waived tests and the limited circumstances in which a payer might accept a distinct service modifier when multiple panels are performed.

Modifier QW: only when the specific assay is waived

CMS issued MLN guidance on new waived tests including 87801QW for certain waived multiplex NAATs. State Medicaid guidance (Texas Medicaid as an example) also reinforces QW use when the test is waived and emphasizes CLIA enrollment requirements. Operational best practice is to maintain a test catalog flag that identifies whether a specific orderable requires QW for Medicare claims and to validate it against the CMS waived-test framework.

Modifier 59 (or related distinct modifiers): uncommon and risky if used to defeat bundling

Because 87801 itself is already a “multiple organisms” code, it is generally incorrect to use modifier 59 to represent multiple organisms or multiple targets. The only scenario where a distinct-service modifier might be contemplated is when a patient truly receives two different multiplex panel procedures on the same date (for example, a rapid small panel early in care and a different panel later due to clinical change), supported by different specimens or different clinical circumstances. Even then, the payer may still deny as redundant or not medically necessary. CMS bundling logic is not intended to be overridden by modifier use when the services are not actually distinct.

Frequency limitations and “one panel per episode” expectations

Although payer-specific frequency tables vary, multiplex panels are commonly treated as once-per-encounter or once-per-episode services unless there is a clear change in clinical status. LCDs for syndromic panels also tend to discourage repetitive use without new justification. As a compliance approach, plan for one unit of 87801 per date of service and treat repeat same-day panels as exceptional events requiring detailed chart support.

Comparison: 87801 vs 87635 vs 87486 vs 87880

The table below differentiates CPT 87801 from commonly confused codes: SARS-CoV-2 NAAT (87635), an organism-specific NAAT example (87486 for Chlamydia pneumoniae), and rapid antigen testing (87880 for Group A strep). The key is matching the code to (a) the number of organisms tested and (b) the detection method.

Documentation Standards and Clinical Scenarios

Documentation is what makes multiplex coding defensible, especially when payers challenge medical necessity or suspect unbundling. The documentation goal is to make it obvious that the billed service was a single multiplex panel (or a specific waived multiplex kit) and to show that the panel scope was appropriate for the patient’s presentation.

Minimum documentation elements

• Test name and platform/panel identification: Record the commercial panel name or the LDT panel description.
• Methodology marker: Identify NAAT/PCR/amplified methodology (often implied in the panel name).
• Pathogen menu or list: Identify the organisms included in the panel. Where listing all is impractical, document a clear reference to the panel’s defined menu and list all targets with individual results if the platform provides them.
• Specimen type and collection timing: Helps support distinct testing when multiple panels are performed.
• Ordering rationale / indication: Clinical syndrome, severity, risk factors, and how results will change management. LCD context for syndromic panels emphasizes that testing should be clinically justified, not routine.

Clinical scenarios

Scenario 1: Waived multi-organism STI panel in a clinic (87801QW)

Setting: A clinic with a CLIA Certificate of Waiver performs a specific FDA-authorized waived multiplex NAAT for multiple STI organisms during a single visit.

Coding: 87801QW when the assay is among those CMS recognized as waived and the payer requires QW.

Compliance note: Claims may deny if QW is omitted or if CLIA enrollment does not match payer files. Texas Medicaid guidance illustrates this operational risk and the requirement for correct CLIA data on file.

Scenario 2: Multiplex respiratory panel vs COVID-only NAAT

Setting: A patient presents with influenza-like illness. If the performed assay tested multiple viruses in one run, multiplex coding may apply. If only SARS-CoV-2 was tested, it is a single-organism NAAT.

Coding: Use 87635 for a SARS-CoV-2-only NAAT as defined in AMA long descriptors. Use a multiplex code only when multiple organisms were actually tested in the same assay (and when a more specific panel code is not available/required).

Compliance note: Document the exact test performed and its targets. “COVID PCR” documentation supports 87635, not 87801.

Scenario 3: Large GI multiplex panel and panel-code expectations

Setting: A comprehensive GI panel is performed on stool using a commercial multiplex platform with many targets.

Coding posture: Manufacturer insurance guides often illustrate that large multiplex GI panels map to defined GI panel codes rather than generic multiplex codes; the BioFire GI Panel insurance guide is a common reference point in billing workflows.

Compliance note: Even if 87801 could describe “multiple organisms,” payers may expect the panel-specific code and may apply LCD medical necessity constraints for syndromic panels.

Scenario 4: Avoiding unbundling when one kit tests multiple organisms

Setting: A multiplex panel is run on a single cartridge that reports several organism results.

Coding: Bill one unit of the appropriate multi-organism/panel code rather than separately billing components. CMS-oriented guidance for infectious disease panels emphasizes “one kit/procedure = one unit” and that component tests are not separately payable in that context.

Compliance note: If a payer sees multiple single-organism NAAT codes for one multiplex run, it may deny or recoup as unbundling. The safest approach is to code the panel as a panel.

Across scenarios, the recurring compliance theme is alignment. The claim must align with the assay format; the documentation must align with the claim; and the test scope must align with coverage expectations for the patient’s clinical setting. When those three align, 87801 billing is typically straightforward. When one is missing (for example, unclear target list, unclear method, or a claim that looks like unbundled panel components), denials and audit risk increase sharply.